Chammartin, Frédérique; Kusejko, Katharina; Pasin, Chloé; Trkola, Alexandra; Briel, Matthias; Amico, Patrizia; Stoekle, Marcel P; Eichenberger, Anna L; Hasse, Barbara; Braun, Dominique L; Schuurmans, Macé M; Müller, Thomas F; Tamm, Michael; Mueller, Nicolas J; Rauch, Andri; Koller, Michael T; Günthard, Huldrych F; Bucher, Heiner C; Speich, Benjamin and Abela, Irene A (2022). Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV. AIDS, 36(10), pp. 1465-1468. Lippincott Williams & Wilkins 10.1097/QAD.0000000000003246
|
Text
Determinants_of_antibody_response_to_severe_acute.17.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (908kB) | Preview |
We identified determinants of SARS-CoV-2 mRNA vaccine antibody response in people with HIV (PWH). Antibody response was higher among PWH less than 60 years, with CD4+ cell count superior to 350 cells/μl and vaccinated with mRNA-1273 by Moderna compared with BNT162b2 by Pfizer-BioNTech. Preinfection with SARS-CoV-2 boosted the antibody response and smokers had an overall lower antibody response. Elderly PWH and those with low CD4+ cell count should be prioritized for booster vaccinations.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology |
UniBE Contributor: |
Eichenberger, Anna |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0269-9370 |
Publisher: |
Lippincott Williams & Wilkins |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
27 Jul 2022 08:48 |
Last Modified: |
05 Dec 2022 16:22 |
Publisher DOI: |
10.1097/QAD.0000000000003246 |
PubMed ID: |
35876706 |
BORIS DOI: |
10.48350/171530 |
URI: |
https://boris.unibe.ch/id/eprint/171530 |
Actions (login required)
 |
Edit item |